• Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
  • KYV-101 is an autologous version of a novel, fully human clinical-stage anti-CD19 chimeric antigen receptor T-cell (CAR T) construct with properties well suited for use in B cell-driven autoimmune diseases such as lupus nephritis and other B-cell driven autoimmune diseases. (pipelinereview.com)
  • Kyverna's pipeline includes next-generation chimeric antigen receptor T-cell (CAR T) therapies in both autologous and allogeneic formats with properties well suited for use in B cell-driven autoimmune diseases. (pipelinereview.com)
  • BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 19, 2019-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the United Kingdom's ( UK ) Medicines Healthcare Products Regulatory Agency (MHRA) has granted authorization of the first-in-human clinical trial to evaluate a Chimeric Antigen Receptor Regulatory T Cell (CAR-Treg) therapy. (sangamo.com)
  • The agreement's initial focus is the research on a targeted allogeneic gamma delta chimeric antigen receptor, or CAR, T-cell therapy owned by Regeneron designed to enhance proliferation and potency against solid tumors. (roi-nj.com)
  • 22, 2021-- Blackstone (NYSE: BX) announced today that funds managed by Blackstone Life Sciences have committed $250 million towards the launch of a new autologous and allogeneic universal chimeric antigen receptor (CAR) T-cell therapy company, along with Intellia Therapeutics, Inc. (NASDAQ: NTLA) and Cellex Cell Professionals GmbH ("Cellex"), the parent company of GEMoaB GmbH ("GEMoaB"), a clinical-stage cell therapy company. (intelliatx.com)
  • Conversely, at the other boundary, immune hypersensitivity with gain of immune function in MHC class II-associated sJIA-AOSD and with chimeric antigen receptor (CAR) T cell therapy also triggers MAS. (nature.com)
  • Khimani (Revvity): Cell and gene therapies are delivering on the promise of curing diseases.Initially starting with CAR-T [chimeric antigen receptor T cells] treatments for hematological malignancies, therapies are now in the clinic for rare inherited genetic disease, infectious diseases, and solid tumors. (biopharminternational.com)
  • Founded in 1999, Cellectis has technology for creating allogeneic chimeric antigen receptor (CAR) T cells by gene editing cells from a healthy donor. (mednous.com)
  • The capital we have raised has formed the launchpad for a world-class, fully integrated allogeneic cell therapy company differentiated from all others," said Ivan Dimov, PhD, Cofounder and Chief Executive Officer of Orca Bio. (orcabio.com)
  • In addition to this, this therapy opens opportunity for designing immunotherapies for tumors lacking well defined neoantigens and without the need of further genetic engineering. (medgadget.com)
  • Under Dr. Cao's leadership, Gracell has been developing a rich pipeline of transformational CAR-T therapies, aiming to broaden the use of breakthrough cell therapies across hematological malignancies, solid tumors and autoimmune conditions. (wowktv.com)
  • Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. (nbc4i.com)
  • Solid tumors, autoimmune diseases, graft versus host disease (GvHD), genetic diseases and neurodegenerative diseases are investigated using many types of autologous and allogeneic cells with rapidly evolving cell engineering and editing approaches. (bdbiosciences.com)
  • This approach enables increased efficacy and safety across a range of cancers, including solid tumors, that are currently a challenge for existing cell therapies. (intelliatx.com)
  • Previously CEO of Zelluna Immunotherapy (2017-2019), where he established the corporate structure, raised successfully, built the team and launched the strategy for solid tumors allogeneic C>. (innovativetherapiesdays.com)
  • The platform technology used in this study can be applied to include additional populations of cells that may further improve survival and decrease complications for patients with leukemia and MDS undergoing allogeneic stem cell transplantation," he says. (emory.edu)
  • Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenia purpura. (astrazenecaclinicaltrials.com)
  • Evans syndrome is the presence of simultaneous or sequential direct Coombs-positive autoimmune hemolytic anemia (AIHA) in conjunction with immune-mediated thrombocytopenia, with no known underlying etiology. (medscape.com)
  • GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. (biospace.com)
  • Investigational cell therapies are addressing a wide range of hematological malignancies. (bdbiosciences.com)
  • These proprietary mixtures have the potential to revolutionize allogeneic cell therapy for hematological and other cancers, as well as many other diseases and disorders. (orcabio.com)
  • HSCT) has significantly modified the prognosis of when the pathological process involves BM or when patients with hereditary or acquired hematological, hematopoietic toxicity is the limiting factor in the oncological and immunological diseases and it is the aggressive treatment of the disease. (bvsalud.org)
  • Kyverna's anti-CD19 CAR T-cell therapy, KYV-101, specifically targets CD19, a protein expressed on the surface of B cells, which are involved in various types of malignancies, including autoimmune diseases. (pipelinereview.com)
  • Patients with other prior malignancies must have had a ≥ 2-year disease-free interval, except for: in situ carcinoma of the cervix, in situ ductal carcinoma of the breast, in situ prostate cancer, in situ bladder cancer. (moffitt.org)
  • Previous malignancies (except non- melanoma skin cancers, and in situ bladder, gastric, colorectal, endometrial, cervical/dysplasia, melanoma , or breast cancers) unless a complete remission was achieved at least 2 years prior to study entry AND no additional therapy is required during the study period. (mycancergenome.org)
  • This can occur, for example, when an allogeneic transplantation patient develops an immune reaction to donor antigens, or when the body responds inappropriately to self antigens implicated in autoimmune diseases. (wikipedia.org)
  • Research using animal models in transplantation and autoimmune diseases has led to early-phase human trials of tolerogenic therapy for autoimmune conditions like Type 1 Diabetes. (wikipedia.org)
  • The department's principal investigators conduct fundamental research on topics including the role of CEACAM1 in T cell activation, TH17 cells and their role in controlling inflammation, graft-versus-host disease in allogeneic hematopoietic cell transplantation (HCT), and the role of T lymphocytes in type 1 diabetes. (cityofhope.org)
  • Jeffrey Wong, M.D., is renowned for his efforts in targeted therapy using image-guided/intensity modulated radiotherapy, recently applying this approach to bone marrow transplantation. (cityofhope.org)
  • TX200 is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation for end-stage renal disease (ESRD). (sangamo.com)
  • This innovative and personalized cellular therapy approach for HLA-A2 mismatched kidney transplantation is designed to help regulate the body's immune system specifically and locally to promote acceptance of an immunologically mismatched donor organ. (sangamo.com)
  • Beyond transplantation, we plan to explore the potential of CAR-Tregs in a range of autoimmune and inflammatory diseases. (sangamo.com)
  • Beyond kidney transplantation, Sangamo intends to use its zinc finger nuclease (ZFN) gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune and inflammatory diseases. (sangamo.com)
  • Therapies for these disorders (eg, intravenous immunoglobulin [IVIG], bone marrow transplantation, gene therapy) are very costly and require highly advanced facilities. (medscape.com)
  • Transplantation & Cellular Therapy Meetings of the American Society of Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR), and the American Society of Hematology (ASH) annual meeting. (emory.edu)
  • Survival after allogeneic transplantation depends on donor-recipient matching, the graft-versus-host response and the development of a graft versus leukemia effect. (emory.edu)
  • In the present study, we retrospectively analyzed all patients with acute leukemia including AML and T-ALL patients with SET-NUP214 fusion who underwent allogeneic stem cell transplantation (alloHSCT) in our center from July 2017 to November 2022. (bvsalud.org)
  • Recurrence following allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the major cause of treatment failure in patients with myeloid malignancy. (bvsalud.org)
  • This prospective clinical investigation focused on the addition of venetoclax and decitabine to myeloablative conditioning regimens, targeting high-risk and elderly individuals undergoing allogeneic hematopoietic stem cell transplantation. (bvsalud.org)
  • The prescribing information includes warnings for dermatologic toxicity, infusion reactions, infections, autoimmune complications, and complications of allogeneic hematopoietic stem cell transplantation. (ascopost.com)
  • 3. Cancer is not the only disease benefited by transplantation. (managedhealthcareexecutive.com)
  • The study also excluded individuals who had prior allogeneic stem cell transplantation and those with hypersensitivity to either drug in the study combination. (clearityfoundation.org)
  • History of organ transplantation, including allogeneic stem cell transplantation. (who.int)
  • Allogeneic stem cell transplantation is the only known curative therapy. (medscape.com)
  • Chronic graft versus host disease (cGVHD) is the most common consequence of allogeneic bone marrow transplantation, and it is associated with morbidity and mortality. (bvsalud.org)
  • Tolerogenic therapies are based on the principle that inducing the semi-mature phenotype in dendritic cells and then exposing them to the target antigen should allow antigen-specific induction of T-cell tolerance. (wikipedia.org)
  • Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. (emory.edu)
  • The specific antigen that triggers lichen planus is unknown, although it may be a self-peptide (or altered self-peptide), in which case lichen planus would be a true autoimmune disease. (medscape.com)
  • Gracell Biotechnologies Inc. ("Gracell") is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. (biospace.com)
  • The company uses its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for the treatment of cancers, other autoimmune diseases, and severe viral infections. (pharmaceutical-technology.com)
  • We are initially focused on two clinical programs in patients with blood cancers and have successfully treated the largest-ever number of patients with a high-precision cell therapy. (orcabio.com)
  • A new Phase 3 clinical trial at Winship is enrolling participants after extremely encouraging results in the study's first two phases indicate the first-in-class high-precision cell therapy retains the benefits of stem cell transplant without such serious complications as graft versus host disease (GvHD) and disease relapse in patients with certain blood cancers. (emory.edu)
  • Cellex Cell Professionals GmbH holds the clinical-stage biopharmaceutical company GEMoaB, which is focused on the development of next-generation immunotherapies and cell therapies for hard-to-treat cancers. (intelliatx.com)
  • Our focus is on providing significantly safer and more efficacious treatments to patients who are suffering from hard-to-treat cancers and autoimmune diseases. (intelliatx.com)
  • A hyperinflammatory 'cytokine storm' state termed macrophage activation syndrome (MAS), culminating from a complex interplay of genetics, immunodeficiency, infectious triggers and dominant innate immune effector responses, can develop across disparate entities including systemic juvenile idiopathic arthritis (sJIA) and its counterpart adult-onset Still disease (AOSD), connective tissue diseases, sepsis, infection, cancers and cancer immunotherapy. (nature.com)
  • There's an "incredibly exciting" amount of research and development in the transplant and cellular therapy space that could result in gamechanging treatments for patients facing blood cancers such as leukemia and lymphoma. (managedhealthcareexecutive.com)
  • I also see a strong commitment in Atara's leadership team to transform the treatment of cancer and autoimmune diseases to improve patients' lives. (atarabio.com)
  • Atara is a leading player in the allogeneic cell therapy field that seeks to harness the power of the immune system to develop novel treatments for patients with cancer and autoimmune diseases. (atarabio.com)
  • FasTCAR is designed to lead the next generation of therapy for cancer and autoimmune diseases, and improve outcomes for patients by enhancing effect, reducing costs, and enabling more patients to access critical CAR-T treatment. (singaporeoutlook.com)
  • FUNDING: US President's Emergency Plan for AIDS Relief through the US Centers for Disease Control and Prevention. (cdc.gov)
  • The stem cell therapy market is segmented into allogeneic and autologous stem cell therapies based on type. (marketsandmarkets.com)
  • Prior allogeneic hematopoietic stem cell transplant (HSCT) or donor lymphocyte infusion within 6 months prior to enrollment, current acute graft versus host disease grade 2-4 by Glucksberg criteria or severity B-D by by International Bone Marrow Transplant Registry (IBMTR) index or history of severe (grade 3-4) acute graft versus host disease. (moffitt.org)
  • Our findings suggest that AZA maintenance therapy following allo-HSCT was safe and could reduce the incidence of relapse, particularly for refractory patients with favorable/intermediate-risk AML. (bvsalud.org)
  • Future research will consider the effectiveness of tolerogenic therapies in a number of planned clinical trials into autoimmune diseases. (wikipedia.org)
  • Currently, no gamma delta T cell therapy has been approved but several are present in clinical trials which are expected to enter the market in next few years. (medgadget.com)
  • Building off experience in hematopoietic stem cell transplant and exploiting advances in genetic engineering, genome editing, immunology, immunotherapy, stem cell biology, understanding disease mechanisms and cell therapy manufacturing, considerable progress has been made with hundreds of clinical trials underway. (bdbiosciences.com)
  • Market growth is driven mainly by factors such as robust funding for stem cell research, an increase in the number of cell therapy production facilities that have GMP certification, and growth in the number of clinical trials associated with stem cell therapies. (marketsandmarkets.com)
  • The surge in the expanding number of clinical trials is further triggered by the COVID-19 pandemic, with a vast number of clinical trials studying the potential of stem cell therapies in the treatment of SARS-CoV-2 infection. (marketsandmarkets.com)
  • This has also led to an increase in the number of clinical trials regarding the development of allogeneic stem cell therapies, making it the fastest growing segment during the forecast period. (marketsandmarkets.com)
  • There are many clinical trials in the cellular therapies space outside of bone marrow transplants, such as CAR-T cell therapy and the use of NK cells, says Ronneberg, noting that a few CAR-T therapies have already received FDA approval. (managedhealthcareexecutive.com)
  • Patients with a history of autoimmune disease resulting in end-organ injury are not eligible unless attributable to primary disease which is target of this study. (moffitt.org)
  • Patients were excluded from the study due to unacceptable toxicity from a prior anti-PD-1 or PD-L1 therapy, active leptomeningeal disease or uncontrolled brain metastases, active autoimmune diseases or history of autoimmune diseases that may relapse, another active malignancy, conditions requiring systemic treatment, and certain infections and disorders. (clearityfoundation.org)
  • Collectively, these mechanisms produce tolerance to specific antigens, which should help to prevent autoimmunity, but could therefore also be used as a therapy to induce tolerance to specific antigens implicated in autoimmune disease, or donor antigens in transplant patients. (wikipedia.org)
  • Where do allogeneic stem cell transplant donor cells come from? (mdanderson.org)
  • Principal investigator Edmund K. Waller, MD, PhD, FACP, says the net result of giving the patient a precise number of donor T cells with specific functions "leads to better elimination of cancer with less graft versus host disease and less toxicity from the transplant. (emory.edu)
  • Winship is one of several clinical trial sites for the Precision-T study evaluating the safety and efficacy of Orca-T, a cell therapy that combines purified cells from a matched donor, in patients with acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and high-risk myelodysplastic sydromes (MDS). (emory.edu)
  • One big improvement has occurred in the realm of allogeneic transplants (in which donor cells are used). (managedhealthcareexecutive.com)
  • Ten to 15 years ago we never sought them for donor transplants (what we call allogeneic transplants). (managedhealthcareexecutive.com)
  • Rethymic ( allogeneic processed thymus tissue-agdc) is processed thymus tissue indicated for immune reconstitution in pediatric patients with congenital athymia. (rxlist.com)
  • POTELIGEO is a CC chemokine receptor type 4 (CCR4)-directed monoclonal antibody indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy ( 1 ). (nih.gov)
  • POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. (nih.gov)
  • Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. (itbusinessnet.com)
  • We believe Geoff's decades-long success record in academia, the military, government and the biopharmaceutical industry will serve Celularity well as we look to progress our pipeline of investigational products to deliver 'off-the-shelf' cellular and regenerative therapies faster, more reliably, and at greater scale to more patients. (itbusinessnet.com)
  • We are immensely proud to have reached this significant milestone in our journey to transform the lives of patients battling life-altering ailments such as LN. Our KYV-101 cell therapy has the potential to revolutionize treatment for individuals suffering from autoimmune diseases, with patients currently being treated for multiple indications across the U.S. and Europe. (pipelinereview.com)
  • As more patients commence their journey with KYV-101, Kyverna continues to explore additional indications for this therapy, as well as develop a robust pipeline of promising immunotherapies aimed at addressing unmet medical needs. (pipelinereview.com)
  • Kyverna recognized that these properties singled out KYV-101 as a product ideally poised for use in autoimmune disease patients, and the company obtained exclusive, worldwide licenses from the National Institutes of Health (NIH) to use this CD19 construct in both autologous and allogeneic CAR T-cell therapies. (pipelinereview.com)
  • To prevent graft rejection, transplanted patients are treated with lifelong immune suppressive therapy, which impacts the body's immune system broadly and is associated with multiple side effects, including an increased risk of infectious complications, cancer, and other drug-related toxicities. (sangamo.com)
  • Sangamo Therapeutics is committed to translating ground-breaking science into genomic medicines with the potential to transform patients' lives using gene therapy, ex vivo gene-edited cell therapy, and in vivo genome editing and gene regulation. (sangamo.com)
  • These are at all stages of development from early preclinical research, as with a neural stem cell therapy being developed for Parkinson's Disease by Axontherapix S.L of Spain, through to products that are available to treat patients now such as Chondroselect ® , a cell therapy for repairing damaged tissue in knee joints produced by Belgian cell therapy firm TiGenix. (eurostemcell.org)
  • Patients with a history of immunodeficiency (except for acquired hypogammaglobulinemia), patients with active autoimmune disease requiring systemic immunosuppressive therapy (i.e. (moffitt.org)
  • 15 mg of prednisone daily or equivalent), or patients who have received any other form of immunosuppressive therapy within 7 days prior to leukapheresis. (moffitt.org)
  • Treatment of relapsed or refractory mycosis fungoides or Sézary syndrome in patients who have previously received ≥1 systemic therapy. (drugguide.com)
  • Monitor patients receiving allogeneic stem cell transplant after receiving mogamulizumab, especially within 50 days after, for signs and symptoms of transplant complications (severe acute graft-versus-host disease [GVHD], steroid-refractory GVHD, transplant-related death). (drugguide.com)
  • Additional focus will be placed on the main classes of immune inhibitor therapy utilized in transplant patients and in autoimmune disease including TNF-alpha, Calcineurin, mTOR, purine synthesis antagonists and IMPDH inhibitors. (mdpi.com)
  • Collaborations like this one are a key instrument for Intellia to strengthen investment in areas of strategic importance to us, enabling us to more quickly realize the full scope and potential of our genome-editing technology for patients in need of more effective therapies. (intelliatx.com)
  • The emergence of more cell therapies has also accelerated development of the technologies needed to support the complex process of extracting immune cells from the blood, engineering them and reinfusing back into patients. (biopharmadive.com)
  • On August 8, the U.S. Food and Drug Administration approved mogamulizumab-kpkc (Poteligeo) injection for intravenous use in the treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. (ascopost.com)
  • The approval of mogamulizumab-kpkc, a CC chemokine receptor type 4-directed monoclonal antibody, was based on a randomized, open-label, multicenter trial (Study 0761-010) in patients with active mycosis fungoides or Sézary syndrome after at least one prior systemic therapy. (ascopost.com)
  • Patients enrolled had received a median of three prior therapies. (ascopost.com)
  • However, through new opportunities, like allogeneic cell therapy, it is hoped that greater benefits to patients, particularly those in undertreated populations, will be achieved (4). (biopharminternational.com)
  • The therapy can be scaled up so that the same product can be used to treat multiple patients, standardizing the product and reducing the cost per patient treated. (biopharminternational.com)
  • In terms of allogeneic transplants, the most common indication is acute myeloid leukemia and myelodysplastic syndrome, which is a blood disorder that affects blood formation in older patients. (managedhealthcareexecutive.com)
  • There are increasing indications not only for patients with cancer, but also for nonmalignant conditions like sickle cell disease and even potentially down the road, autoimmune diseases like multiple sclerosis," says Devine. (managedhealthcareexecutive.com)
  • Autologous and allogeneic mesenchymal stem cells have been safely administered to individuals with hemato-oncological diseases and in a limited number of patients with multiple sclerosis. (drcalapai.com)
  • An additional 8 patients demonstrated stable disease. (clearityfoundation.org)
  • Patients with early-stage CLL are not treated with chemotherapy until they become symptomatic or display evidence of rapid progression of disease. (medscape.com)
  • Chemotherapy is not needed in CLL until patients become symptomatic or display evidence of rapid progression of disease. (medscape.com)
  • Of possible significance, elevated concentrations of interleukin-6 (IL-6) and neopterin in saliva and serum of patients with the erosive-atrophic form of oral lichen planus suggest they may be involved in the etiology of this disease variation. (medscape.com)
  • The role of autoimmunity in the pathogenesis is supported by many autoimmune features of oral lichen planus, including its chronicity, onset in adults, predilection for females, association with other autoimmune diseases, occasional tissue-type associations, depressed immune-suppressor activity in patients with oral lichen planus, and the presence of autocytotoxic T-cell clones in lichen planus lesions. (medscape.com)
  • Le pourcentage de CD44 dans les lymphocytes T périphériques était significativement plus élevé chez les patients que chez les témoins, comme détecté par la cytométrie en flux. (who.int)
  • En outre, il y avait une aug- mentation significative de la forme soluble du c-kit dans le sérum des patients atteints de pemphigus vulgaire actif par rapport aux témoins. (who.int)
  • Comparatively fewer complications are associated with the development and manufacturing of allogeneic stem cell therapies, which is the key attributive reason for their largest share in the market. (marketsandmarkets.com)
  • Studies have suggested a role for tolerogenic dendritic cells in the treatment of diseases like type 1 diabetes mellitus and multiple sclerosis. (wikipedia.org)
  • Finally, members of the Department of Immunology & Theranostics are pursuing immunological approaches to detection and treatment of disease. (cityofhope.org)
  • GC012F is Gracell's FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. (biospace.com)
  • and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. (seekingalpha.com)
  • Biotech products include protein drugs made by genetically-engineered cell cultures, monoclonal antibodies (laboratory-made copies of a single human antibody, often for use in cancer treatment ) and, most recently, human cell-based therapies. (eurostemcell.org)
  • The company has developed a proprietary and patented platform technology to produce mesenchymal stromal cells adapted for allogeneic treatment of various autoimmune and immunological diseases. (nextcellpharma.com)
  • We believe our approach has the potential to transform allogeneic cell therapy, and thus the treatment of not only blood cancer, but also many other diseases with significant unmet need, such as a variety of genetic diseases and autoimmune disorders. (orcabio.com)
  • Vaccine recommendations are based on characteristics of the immunobiologic product, scientific knowledge regarding the principles of active and passive immunization, the epidemiology and burden of diseases (i.e., morbidity, mortality, costs of treatment, and loss of productivity), the safety of vaccines, and the cost analysis of preventive measures as judged by public health officials and specialists in clinical and preventive medicine. (cdc.gov)
  • Note: Subjects with vitiligo, Grave's disease, limited site eczema, or limited site plaque psoriasis not requiring systemic treatment (within the past 2 years), or other autoimmune conditions which are not expected to recur, are allowed after approval from the medical monitor or PI. (moffitt.org)
  • In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. (mayo.edu)
  • The Precision-T study is funded by Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders. (emory.edu)
  • Since then, five other so-called CAR-T cell therapies have joined that treatment on the U.S. market for several types of leukemia, lymphoma and multiple myeloma. (biopharmadive.com)
  • Studies have begun to support their use earlier in a patient's disease , rather than after all other treatment options have been exhausted. (biopharmadive.com)
  • The investigators will be looking at both the side effects and the way the disease responds to treatment. (mycancergenome.org)
  • Ongoing immunosuppressive therapy, including systemic or enteric corticosteroids for treatment of CLL or other conditions. (astrazenecaclinicaltrials.com)
  • Women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to the first dose of study treatment. (survivornet.com)
  • Dr. Zhang will present on the application of next-generation CAR-T cell therapies for treatment of autoimmune disease, highlighting insights from Gracell's development of FasTCAR-enabled CD19/BCMA dual-targeting GC012F in SLE, and the translational research supporting the potential benefit of dual-targeting in maximizing depletion of disease-causing B-cells and plasma cells. (singaporeoutlook.com)
  • Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease. (who.int)
  • Any autoimmune disease requiring systemic treatment in the past 5 years. (who.int)
  • Reported associations between oral lichen planus and systemic diseases may be coincidental, because (1) oral lichen planus is relatively common, (2) oral lichen planus occurs predominantly in older adults, and (3) many drugs used in the treatment of systemic diseases trigger the development of oral lichenoid lesions as an adverse effect. (medscape.com)
  • In addition, the complexities of regulations in this area require federal guidelines that can support researchers, scientists, and pharmaceutical companies to develop ESC therapy and further facilitate its commercialization. (marketsandmarkets.com)
  • I look forward to the Orca Bio team's continued development and commercialization of revolutionary allogeneic cell therapies. (orcabio.com)
  • Based on cell source, the stem cell therapy market is segmented into adipose tissue-derived MSCs (mesenchymal stem cells), placental/umbilical cord-derived MSCs, bone marrow-derived MSCs, and other sources. (marketsandmarkets.com)
  • Replacing bone marrow transplants is a logical first step in next-generation allogeneic cell therapy. (orcabio.com)
  • While a conventional bone marrow transplant administers an uncontrolled cell product, Orca Bio has been the first to deliver a high-precision cell therapy. (orcabio.com)
  • With precise reconstitution using highly defined cell preps and a swift reboot of the patient's immune system, Orca Bio's product candidates have the potential to eliminate fatal side effects, such as graft-versus-host disease, and infections commonly associated with bone marrow transplants while maintaining or enhancing antitumor efficacy," said Rick Klausner, MD, an investor and member of Orca Bio's advisory board. (orcabio.com)
  • He has published numerous research papers on innovative cellular therapies. (itbusinessnet.com)
  • Dr. Ling commented on his new role, "I am thrilled to join the board of Celularity, a company known for its groundbreaking work in cellular therapies. (itbusinessnet.com)
  • The agreement with Regeneron announced today is an important milestone for Celularity that recognizes our expertise in the research of cellular therapies, including the engineering of CAR-T cells. (roi-nj.com)
  • Celularity, headquartered in Florham Park, is a biotechnology company leading the next evolution in cellular and regenerative medicine by developing allogeneic cryopreserved off-the-shelf placental-derived cell therapies, including therapeutic programs using mesenchymal-like adherent stromal cells, or MLASCs, T-cells engineered with CAR, and genetically modified and unmodified natural killer, or NK, cells. (roi-nj.com)
  • Mesenchymal stem cells (MSCs) have been suggested as an appropriate source for diabetes cell-based therapies. (biomedcentral.com)
  • Mesenchymal stem cells modulate pathological responses in experimental autoimmune encephalitis, alleviating disease, but also stimulate repair of the central nervous system through the release of soluble factors. (drcalapai.com)
  • Kyverna Therapeutics Announces First Patient Enrolled in Phase 1 Clinical Trial of CD19 CAR T-cell Therapy for Lupus Nephritis in the U.S. (pipelinereview.com)
  • Kyverna Therapeutics is a cell therapy company with the mission of engineering a new class of therapies for autoimmune and inflammatory diseases. (pipelinereview.com)
  • The International Society of Cell and Gene Therapy is the global leader in pre-clinical and translational cell and gene therapeutics. (nextcellpharma.com)
  • Freeline Therapeutics Holdings Plc, a UK gene therapy company, is to become a private company once again following an agreement with a portfolio company of Syncona, its majority shareholder and co-founder, to acquire all of the shares that Syncona doesn't already own. (mednous.com)
  • Agomab Therapeutics NV, a Belgian biotech founded in 2017 to explore the potential of a critical biological pathway to achieve tissue repair, closed a $100 million Series C financing round on 11 October to support clinical development of a drug for fibrostenosing Crohn's disease. (mednous.com)
  • Cell therapies are treatments that use human cells, including stem cells, with the aim of restoring, maintaining, or improving the functioning of human tissues or organs. (eurostemcell.org)
  • Medical records research - uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best. (mayo.edu)
  • Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. (mayo.edu)
  • Orca-T is intended to avoid the significant risks of GvHD and disease relapse associated with standard treatments. (emory.edu)
  • This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medscape, LLC and Emerging Infectious Diseases. (cdc.gov)
  • Emerging Infectious Diseases. (cdc.gov)
  • Faculty conduct research on bacterial, viral and fungal infectious diseases, including detection and vaccine development, supported by state-of-the-art facilities in mass spectrometry and NMR. (cityofhope.org)
  • National Institutes of Allergy and Infectious Diseases. (biopharmadive.com)
  • Holds an M.D. and Specialist in Infectious Diseases from the Faculty of Medicine, University of Lisbon, a Ph.D. in Immunology, University of Birmingham, and a certificate on Health Technologies Economics, Stockholm School of Economics. (innovativetherapiesdays.com)
  • Tolerogenic therapy aims to induce immune tolerance where there is pathological or undesirable activation of the normal immune response. (wikipedia.org)
  • Tolerogenic therapies employ the inbuilt tolerance mechanisms of a class of immune cells called dendritic cells. (wikipedia.org)
  • Short course immune induction therapy Bluestone JA, Thomson AW, Shevach EM, Weiner HL (August 2007). (wikipedia.org)
  • CAR T-cell therapy involves modifying a patient's immune T cells to recognize and remove B cells in the patient's body. (pipelinereview.com)
  • The Kyverna therapeutic platform combines advanced T-cell engineering and synthetic biology technologies to suppress and eliminate the autoreactive immune cells at the origin of autoimmune and inflammatory diseases. (pipelinereview.com)
  • Classifying MAS using the immunological disease continuum model, with strict boundaries that define the limits of innate and adaptive immunity, at one boundary is MAS with loss of immune function, as occurs in the 'perforinopathies' and some cases of sJIA-AOSD. (nature.com)
  • Dysregulated production of IFNγ and other pivotal cytokines including IL-1, IL-6 and IL-18 can arise from either loss or gain of function in the immune response, with different implications for therapy and prognosis. (nature.com)
  • Considering the boundaries of immunodeficiency and immune hypersensitivity in MAS related to systemic juvenile idiopathic arthritis and adult-onset Still disease, and the role of lymphoid cells, severe COVID-19 is generally a distinctive lung-specific immunopathology. (nature.com)
  • Lymphocytes are a type of white blood cell that support our immune system by fighting infection and disease. (lymphoma.org.au)
  • Because our lymphocytes fight infection and disease, they are part of our immune system. (lymphoma.org.au)
  • This affects your immune system's ability to keep you healthy and protect you from infections and disease. (lymphoma.org.au)
  • graft versus host disease. (rxlist.com)
  • Monitor for severe acute graft-versus-host disease (GVHD) and steroid-refractory GVHD. (nih.gov)
  • This is called graft-versus-host disease. (mdanderson.org)
  • Graft versus host disease can cause severe damage to the skin, liver, intestines and lungs," Waller says. (emory.edu)
  • We've managed to be able to reduce the rates of severe graft-versus-host disease-that's the major complication of transplants," says Devine. (managedhealthcareexecutive.com)
  • Chronic graft-vs-host disease (cGVHD) is the most common complication following allogeneic BMT [10]. (bvsalud.org)
  • Many other clinical conditions present substantial skin fibrosis and may be potentially confused with Scleroderma, sometimes leading to a wrong diagnosis (eosinophilic fasciitis, systemic amyloidosis, scleromyxedema, graft-versus-host disease, progeroid disorders, stiff skin syndrome). (bvsalud.org)
  • In 2021, the adipose tissue-derived stem cells segment dominated stem cell therapy with the highest revenue share, which was attributed to the growing adoption of these MSCs across different therapeutic indications. (marketsandmarkets.com)
  • Based on therapeutic application, the stem cell therapy market is segmented into musculoskeletal disorders, cardiovascular diseases, wounds and injuries, neurological disorders, surgeries, inflammatory and autoimmune diseases, and other therapeutic applications. (marketsandmarkets.com)
  • GEMoaB is developing a switchable universal platform to improve the therapeutic window of CAR T-cell therapies. (intelliatx.com)
  • The increasing number of processes being developed to address the cell therapy market will need to be consolidated at some point to create a standardized, scalable therapeutic approach. (biopharminternational.com)
  • In particular, Ronneberg points to recent FDA approvals in the cellular therapy space and the high amount of venture funding going into emerging therapeutic companies-about $7 billion last year-as promising trends. (managedhealthcareexecutive.com)
  • The Roche Group is to pay $7.1 billion upfront to acquire Telavant Holdings Inc, developer of a late-stage antibody therapeutic for inflammatory bowel disease (IBD). (mednous.com)
  • Stem cell transplants fall into two categories: autologous and allogeneic. (mdanderson.org)
  • An allogeneic stem cell transplant is similar, but we take cells from someone other than the patient. (mdanderson.org)
  • Throughout his career, Dr. Ling has made significant contributions to regenerative medicine and stem cell therapy, earning him recognition as a thought leader in these areas. (itbusinessnet.com)
  • Leveraging Dr. Ling's outside perspective and deep expertise in stem cell therapy, Celularity hopes to unlock the full potential of placental-derived cells and tissues. (itbusinessnet.com)
  • The global stem cell therapy market in terms of revenue was estimated to be worth $257 million in 2022 and is poised to reach $558 million by 2027, growing at a CAGR of 16.8% from 2022 to 2027. (marketsandmarkets.com)
  • Lack of proper federal policies that define what can be funded in embryo-based stem cell research or therapy development may restrain the market's expansion in the future to a certain extent. (marketsandmarkets.com)
  • The adipose tissue-derived stem cell segment dominated the stem cell therapy indsutry. (marketsandmarkets.com)
  • The musculoskeletal disorders segment has generated highest revenue in the stem cell therapy industry. (marketsandmarkets.com)
  • In recent decades, stem cell-based therapies have raised hopes for treating incurable diseases such as diabetes [ 3 ]. (biomedcentral.com)
  • This book also has a dedicated section on Regenerative Medicine with chapters on platelet rich plasma, stem cell therapy, and intradiscal regenerative therapy. (nshealth.ca)
  • Ronneberg and Steven Devine, MD, stem cell transplant physician and medical director at Be The Match BioTherapies, recently spoke with Managed Healthcare Executive to discuss developments in the transplant and cellular therapy space. (managedhealthcareexecutive.com)
  • Each therapy is constructed by formulating a proprietary mixture of cells that aims to cure the patient's disease and eliminate dangerous side effects. (orcabio.com)
  • FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) - Celularity Inc. (Nasdaq: CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. (itbusinessnet.com)
  • Researchers hope to use stem cells to repair or replace cells or tissues damaged or destroyed by such disorders as Parkinson disease, diabetes, and spinal injuries. (msdmanuals.com)
  • Pemphigus vulgaris (PV) is a life-threate- disorders and to shed a light on the role of ning blistering skin disease in which pa- mast cells in autoimmune diseases [ 7 ]. (who.int)
  • The condition often shares the features of a variety of autoimmune diseases, such as lichen planus, Sjögren's syndrome, systemic lupus erythematosus or primary biliary cirrhosis [12, 13]. (bvsalud.org)
  • Current data suggest that oral lichen planus (OLP) is a T-cell-mediated autoimmune disease in which autocytotoxic CD8 + T cells trigger the apoptosis of oral epithelial cells. (medscape.com)
  • Have cytoscopic evidence of measurable disease. (moffitt.org)
  • There is no minimum measurement to be considered measurable disease. (moffitt.org)
  • NOTE: Tumor lesions in a previously irradiated area are not considered measurable disease. (mayo.edu)
  • Measurable disease per RECIST v1.1. (ucsd.edu)
  • Measurable disease defined as lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 10 mm with CT scan or MRI. (mycancergenome.org)
  • To be included in the phase Ib study, individuals were required to be at least 18 years of age, have at least 1 measurable disease lesion, have an ECOG performance status ≤ 1, and adequate hematologic and end-organ function. (clearityfoundation.org)
  • Measurable disease based on either radiographic imaging per RECIST 1.1 or WHO criteria. (who.int)
  • Stem cells have much greater potential to treat chronic health conditions affecting large numbers of people including diabetes, heart disease, neurodegenerative and autoimmune illnesses. (eurostemcell.org)
  • Syncona co-founded Freeline in 2015 with the aim of developing gene therapies for chronic debilitating diseases. (mednous.com)
  • Diagnosis of primary immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent. (who.int)
  • Clinical manifestations of chronic GVHD are similar to autoimmune collagen vascular disease and the two main types of cutaneous chronic GVHD are lichenoid and sclerodermatous. (bvsalud.org)
  • The typical clinical course is chronic and relapsing, and therapy is generally progressive and poor. (medscape.com)
  • Chronic Lymphocytic Leukemia (CLL) is also considered a subtype of NHL as it is essentially the same disease as Small Lymphocytic Lymphoma . (lymphoma.org.au)
  • History of pneumonitis or drug-related inflammatory lung disease. (moffitt.org)
  • History or evidence of interstitial lung disease including noninfectious pneumonitis. (who.int)
  • Other countries such as Spain and Switzerland have made significant investments in regenerative medicine and can be considered 'emerging' or secondary sites of strength in the European cell therapy field. (eurostemcell.org)
  • Cell-based therapies may provide a new strategy for bolstering regeneration and repair through neuro-axonal protection or remyelination. (drcalapai.com)
  • Co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund, the money will be used to develop VTx-002 and other programmes for neurodegenerative diseases. (mednous.com)
  • Administer on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity. (nih.gov)
  • Any unresolved toxicity (>CTCAE v5 grade 2) from previous anti-cancer therapy. (moffitt.org)
  • Continue until disease progression or unacceptable toxicity. (drugguide.com)
  • Mogamulizumab-kpkc is administered on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of subsequent 28-day cycles until disease progression or unacceptable toxicity. (ascopost.com)
  • Toxicity from prior therapy that has not recovered. (who.int)
  • Patient underwent allogeneic BTM and two days later developed acute GVHD on intestine. (bvsalud.org)
  • GVHD disease is the most common consequence of allogeneic BMT and the skin is the most commonly affected organ [5, 13]. (bvsalud.org)
  • IL-10 produced by T regulatory cells was important in suppressing the mouse thyroglobulin specific T cell response and therefore protecting against Experimental autoimmune thyroiditis in mice. (wikipedia.org)
  • For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s). (astrazenecaclinicaltrials.com)
  • The purpose of the study is to evaluate the feasibility, safety and tolerability of intravesical adoptive cell therapy using TIL (tumor infiltrating lymphocytes) in participants with urothelial cell carcinoma (UCC) non-muscle invasive bladder cancer (NMIBC). (moffitt.org)
  • The cell surface protein Fas (CD95) and its ligand play a pivotal role in regulating lymphocyte apoptosis, and defective expression of either Fas or Fas ligand results in marked overaccumulation of mature lymphocytes and autoimmune disease in mice. (medscape.com)
  • Our lymphatic system is also where our B-cell lymphocytes make disease fighting antibodies. (lymphoma.org.au)
  • NextCell Pharma AB's ('NextCell' or the 'Company') CSO, Lindsay Davies, has been nominated for the position of European Regional Secretary for the International Society for Cell and Gene Therapy. (nextcellpharma.com)
  • At the forefront of cell and gene therapy (CGT), ISCT provides a global platform influencing and spearheading policy development, regulations and cutting edge research through their committees, positional papers, and training programs. (nextcellpharma.com)
  • These forward-looking statements include, without limitation, statements regarding the potential benefits of cell therapy, including but not limited to Treg therapy, the Company's ability to develop and commercialize product candidates to address genetic diseases with the Company's proprietary technologies and the timing of commencement or next stages of such programs and the anticipated benefits therefrom. (sangamo.com)